西妥昔单抗诱导皮肤毒性与早期肿瘤退缩在转移性结直肠癌中的关系:FIRE-3随机3期试验结果
FIRE-3试验纳入RAS野生型转移性结直肠癌患者,比较FOLFIRI联合西妥昔单抗与FOLFIRI联合贝伐珠单抗一线治疗。回顾性分析显示,仅在西妥昔单抗诱导皮肤毒性≥2级的患者中,FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗显著改善总生存;皮肤毒性与早期肿瘤退缩均为独立预后因素。
要点
- 仅在西妥昔单抗皮肤毒性≥2级患者中,FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗显著改善总生存。
- 皮肤毒性≥2级与早期肿瘤退缩均为总生存的独立预后因素。
- 皮肤毒性≥2级与早期肿瘤退缩均缺失的患者预后极差,中位总生存15.1个月。
核心结论
- 在FIRE-3中,仅在西妥昔单抗诱导皮肤毒性≥2级的患者中,FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗显著改善总生存。
- 西妥昔单抗诱导皮肤毒性与早期肿瘤退缩均为总生存的独立早期预后因素。
- 联合评估治疗中参数如皮肤毒性和早期肿瘤退缩可能有助于指导转移性结直肠癌的治疗。
研究设计与样本
- FIRE-3为随机3期试验,评估一线FOLFIRI联合西妥昔单抗对比FOLFIRI联合贝伐珠单抗治疗RAS野生型转移性结直肠癌患者。
- 回顾性分析第1-3周期治疗期间发生的西妥昔单抗诱导皮肤毒性数据,并与疗效终点(包括早期肿瘤退缩)进行相关性分析。
- 为控制保证时间偏倚,仅纳入完成3个或以上治疗周期的患者。
主要发现
- 199例接受FOLFIRI联合西妥昔单抗治疗的患者中,181例(91.0%)完成3个或以上治疗周期。
- 西妥昔单抗皮肤毒性2-3级患者中,FOLFIRI联合西妥昔单抗较FOLFIRI联合贝伐珠单抗显著改善总生存(41.0个月 vs 26.6个月;HR=0.73;95%CI 0.61-0.87;P<0.001)。
- 西妥昔单抗皮肤毒性0-1级患者中,两组总生存无显著差异(HR=0.90;95%CI 0.67-1.20;P=0.48)。
- 西妥昔单抗皮肤毒性2-3级(n=75;41.4%)较0-1级(n=106;58.6%)与更长的总生存相关(HR=0.62;95%CI 0.42-0.91;P=0.01)。
- 多因素分析中,西妥昔单抗皮肤毒性(HR=0.66;95%CI 0.50-0.87;P=0.003)和早期肿瘤退缩(HR=0.55;95%CI 0.41-0.74;P<0.0001)均为总生存的独立预后因素。
临床怎么用
- 西妥昔单抗治疗期间出现皮肤毒性≥2级可能提示生存获益,可结合早期肿瘤退缩评估治疗反应。
- 皮肤毒性≥2级和早期肿瘤退缩均缺失的患者预后极差,需考虑更密切的随访或治疗调整。
局限性
- 西妥昔单抗诱导皮肤毒性数据为回顾性收集。
- 分析仅纳入完成3个或以上治疗周期的患者以控制保证时间偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for targeted therapy, we investigated its prognostic impact with early tumor shrinkage (ETS) ≥20%, another on-treatment surrogate for clinical outcome in FIRE-3. PATIENTS AND METHODS: FIRE-3 evaluated first-line FOLFIRI (folinic acid, fluorouracil and irinotecan) plus cetuximab (FOLFIRI/Cet) versus FOLFIRI plus bevacizumab (FOLFIRI/Bev) in mCRC patients with RAS-WT tumors (i.e. wild-type in KRAS and NRAS exons 2-4). Retrospective data on Cet-ST that occurred during cycles 1-3 of treatment were correlated with efficacy endpoints, including ETS. To control for guarantee-time bias, only patients who had completed three or more treatment cycles were considered. RESULTS: Of 199 patients treated with FOLFIRI/Cet, 181 (91.0%) completed three or more treatment cycles. A significant survival benefit of FOLFIRI/Cet over FOLFIRI/Bev was only evident in patients developing Cet-ST grade 2-3 [41.0 versus 26.6 months; hazard ratio (HR) = 0.73; 95% confidence interval (CI): 0.61-0.87; P < 0.001] compared with Cet-ST grade 0-1 (HR = 0.90; 95% CI: 0.67-1.20; P = 0.48). Regarding prognosis, Cet-ST grade 2-3 (n = 75; 41.4%), compared with Cet-ST grade 0-1 (n = 106; 58.6%), was associated with prolonged overall survival (OS; HR = 0.62; 95% CI: 0.42-0.91; P = 0.01). In multivariate analysis, both Cet-ST (HR = 0.66; 95% CI: 0.50-0.87; P = 0.003) and ETS (HR = 0.55; 95% CI: 0.41-0.74; P < 0.0001) were independently prognostic for OS. Absence of both Cet-ST grade ≥2 and ETS identified a subgroup of patients with very poor prognosis (median OS 15.1 months). CONCLUSIONS: In FIRE-3, the addition of cetuximab to FOLFIRI was associated with superior OS compared with FOLFIRI/Bev only in patients developing Cet-ST grade ≥2. Regarding prognostic relevance, both Cet-ST and ETS were independent and early predictors of survival. The present analysis supports that a combined evaluation of on-treatment parameters such as Cet-ST and ETS may help to guide treatment of mCRC.
引用
- Holch JW, Held S, Stintzing S, et al. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). Ann Oncol. 2020. PMID: 31912799. doi:10.1016/j.annonc.2019.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。